New Drug to Fight Alzheimer's Disease Soon from AstraZeneca, Eli Lilly Combo

British drugmaker AstraZeneca and Eli Lilly of the United States announced a partnership on Tuesday to develop a new drug aimed at treating Alzheimer's disease, the most common form of dementia.

Alzheimer's disease is a neurodegenerative disorder in which a buildup of amyloid plaque in the brain destroys neurons. The disease is rapidly growing and poses the biggest challenge in medical science.

Alzheimer’s disease - Causes, Symptoms, Diagnosis, Stages, Types, Prevention, Prognosis & Treatment
Alzheimer's disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.

Only a handful of drugs are available to treat the symptoms of Alzheimer's that can include memory loss, confusion, irritability, aggression and mood swings.

The idea behind the prototype drug is to disrupt the build up of neuron-destroying plaque.

The drug's designers hope that an "inhibitor" targeting an enzyme called BACE that plays a key part in the buildup of plaque will slow progression of the disease.

Alzheimer�s Disease Day: Treating Dementia with Care Rather Than Cure
Alzheimer’s disease has no cure and patients need care more than cure, says Ravi Samuel, Cognitive Behavior & Cognitive Rehabilitation Psychotherapist.

"AstraZeneca and Eli Lilly ... today announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease," the companies said in a statement.

Under the deal, Lilly will pay AstraZeneca up to $500 million (386 million euros) if the drug reaches key development and regulatory milestones.

Caring for Alzheimers disease patients
Alzheimer's disease is a complex brain disorder that triggers the most common form of dementia. The slide show will show how patients need support and care as dementia progresses.

AstraZeneca added that AZD3293 has been shown in Phase 1 studies -- the first in the lengthy three-step process to vet a new drug for safety and effectiveness -- to significantly reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy counterparts.

"Alzheimer's disease is one of the biggest challenges facing medical science today and BACE inhibitors have the potential to target one of the key drivers of disease progression," said Mene Pangalos, AstraZeneca's executive vice president of innovative medicines and early development, in the statement.

Diseases Related to Old Age
Ageing is referred to the accumulation of changes that brings a person closer to death.

Health systems in Western countries are struggling to deal with Alzheimer's as it is costly to treat sufferers of the incurable disease which leaves sufferers increasingly reliant on assistance.

Source-AFP